prbd News

Press Releases for Biosimilars

787

Biotechnology Industry 2010 Yearbook

In 2009 the Biotechnology Industry was Dominated by the Top 10 Companies
By : | 11-23-2010 | Health and Fitness:Healthcare | Total Views : 787
568

The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes

The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
By : | 01-12-2012 | Health and Fitness:Health and Fitness | Total Views : 568
854

New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen

Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
By : | 11-29-2011 | Medical:Medical | Total Views : 854
733

Entry of Biosimilars will Expand the Demand of Cold Chain Logistic Services

A New Report from IMARC Group expects the growth of the biosimilar market to expand the demand of cold chain logistic services in the coming years.
By : | 11-28-2011 | Industry:Industry | Total Views : 733
630

Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020

Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
By : | 11-17-2011 | Business:Markets | Total Views : 630
589

Amgen to be the Worst Hit from US Biosimilar Erosion During 2011 – 2020

A new report from IMARC Group expects Amgen to lose brand sales worth US$ 8.4 Billion during 2010 and 2020 mainly as a result of biosimilar erosion.
By : | 10-11-2011 | Health and Fitness:Healthcare | Total Views : 589
741

The Market for Biosimilars Will be a Marathon and Not a Sprint

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
By : | 07-27-2011 | Health and Fitness:Health and Fitness | Total Views : 741
553

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Dri

Patent Expiries in Near Future Will Drive Generics’ Growth
By : | 05-11-2011 | Health and Fitness:Healthcare | Total Views : 553

Page 1 of 1

TOP 10 PR Updates